Linked Life Data

20350127

Source:http://linkedlifedata.com/resource/pubmed/id/20350127

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-3-30
pubmed:abstractText
Hypertension pharmacogenomics holds the promise of leading to individualized drug treatment approaches for the approximately 1 billion individuals worldwide with hypertension. Prior to 2000, the literature on hypertension pharmacogenomics was quite limited. The last decade has seen a substantial growth in the literature, with several examples of genes that appear to play an important role in antihypertensive response. The last decade has also made apparent the numerous challenges in hypertension pharmacogenomics, and addressing those challenges will be important. Moving forward, it seems clear that collaboration among researchers to allow replication or joint analyses will be essential in advancing the field, as will the use of genome-wide association approaches. The next decade should clearly define the clinical potential for hypertension pharmacogenomics.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1744-8042
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
487-91
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Pharmacogenomics of antihypertensive drugs: past, present and future.
pubmed:affiliation
Department of Pharmacotherapy & Translational Research & Center for Pharmacogenomics, University of Florida, Box 100486, Gainesville, FL 32610-0486, USA. johnson@cop.ufl.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural